Organization (Nonprofit)
CANCER RESEARCH UK
ClinicalTrials.gov lists CANCER RESEARCH UK as lead sponsor of 83 trials. It has 249 active development programs and 52 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 10 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 12 in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers CANCER RESEARCH UK: 83 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (145)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 34 |
| Lymphoma | 31 |
| Breast Neoplasms | 29 |
| Head and Neck Neoplasms | 27 |
| Carcinoma, Non-Small-Cell Lung | 25 |
Showing 5 of 145 disease areas.
Trials by start year as sponsor or collaborator (33)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2025 | 2 |
| 2024 | 9 |
| 2023 | 11 |
| 2022 | 11 |
| 2021 | 9 |
| 2020 | 9 |
| 2019 | 13 |
| 2018 | 11 |
| 2017 | 15 |
Showing 10 of 33 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; 10 of 10 predicted trials reach the 36-month horizon; registered median of 54 months across 37 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (249)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Capmatinib | Hematologic Neoplasms | Phase 2/3 | 2 |
| Alectinib | Hematologic Neoplasms | Phase 2/3 | 2 |
| Entrectinib | Hematologic Neoplasms | Phase 2/3 | 2 |
| Vemurafenib | Thyroid Cancer, Papillary | Phase 2/3 | 1 |
| Trastuzumab in combination with pertuzumab | Hematologic Neoplasms | Phase 2/3 | 1 |
Showing 5 of 249 active programs.
Approved assets (52)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Vincristine | 4 |
| METHOTREXATE | 3 |
| GEMCITABINE | 2 |
| "Capecitabine" | 2 |
| Calcium Leucovorin | 2 |
Showing 5 of 52 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=12) | 43% on time (n=14) |
Journals published in (106)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Lancet. Oncology | 21 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 20 |
| BMJ open | 16 |
| BMC cancer | 13 |
| British journal of cancer | 13 |
Showing 5 of 106 journals.
Financing and grant events (5)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-08-01 | NIH grant | 1,640,929 | Reporter |
| 2024-09-09 | NIH grant | 819,783 | Reporter |
| 2023-08-21 | NIH grant | 1,113,831 | Reporter |
| 2022-09-19 | NIH grant | 832,330 | Reporter |
| 2021-05-10 | NIH grant | 913,614 | Reporter |
Organization relationships (87)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Institute of Cancer Research, United Kingdom | Co sponsors trial with | 11 |
| Stand Up To Cancer | Co sponsors trial with | 6 |
| NHS Greater Glasgow and Clyde | Co sponsors trial with | 5 |
| National Institute for Health Research, United Kingdom | Co sponsors trial with | 4 |
| HonorHealth Research Institute | Co sponsors trial with | 4 |
Showing 5 of 87 relationships.
Latest dated events (280)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 280 events.
Biomarker capability evidence (772)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCD1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Primary endpoint in a Phase 3 trial |
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 772 evidence rows.
On Scientist.com
CANCER RESEARCH UK is listed as a research supplier in the Scientist.com network.
We want survival in the UK to be among the best in the world. We’re focusing our efforts in four key areas – working to help prevent cancer, diagnose it earlier, develop new treatments and optimise current treatments by personalising them and making them even more effective. We’ll continue to support research into all types of cancer and across all age groups. And we’re keeping our focus on understanding the biology of cancer so we can use this vital knowledge to save more lives. We’re increasing our research in key areas such as early diagnosis, and hard-to-treat cancers including lung...
Show the full description
We want survival in the UK to be among the best in the world. We’re focusing our efforts in four key areas – working to help prevent cancer, diagnose it earlier, develop new treatments and optimise current treatments by personalising them and making them even more effective.
We’ll continue to support research into all types of cancer and across all age groups. And we’re keeping our focus on understanding the biology of cancer so we can use this vital knowledge to save more lives.
We’re increasing our research in key areas such as early diagnosis, and hard-to-treat cancers including lung, pancreatic, oesophageal cancers and brain tumours.
We’re developing new tests, surgery and radiotherapy techniques, and cancer drugs. We want to personalise prevention, screening and treatment and bring benefits to patients sooner.
To help accelerate progress, we’ll be investing an additional £50 million a year into new funding schemes for our researchers. These will encourage collaboration and innovation, and support research tackling some of the biggest scientific challenges in cancer research.
Smoking is the biggest preventable cause of cancer and we’ll work towards the day when no one in the UK smokes – in particular by protecting children and helping people to quit.
We’ll campaign for the best cancer services in all parts of the UK, and give more people the chance to join the fight against cancer.
But we can’t achieve our mission alone. We rely on our dedicated scientists, doctors and nurses, and the generosity of our supporters across the UK. With your help, we can beat cancer sooner.
- Website
- www.cancerresearchuk.org
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Cancer Research UK on Scientist.com
For prices, more details, or to contact Cancer Research UK, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.